MDG1 Fundamental Analysis - MEDIGENE AG

Fundamental Rating

Taking everything into account, MDG1 scores 2 out of 10 in our fundamental rating. MDG1 was compared to 83 industry peers in the Biotechnology industry. While MDG1 seems to be doing ok healthwise, there are quite some concerns on its profitability. MDG1 is valied quite expensively at the moment, while it does show a decent growth rate.

Quickly go to:

1. Profitability

1.1 Basic Checks

In the past year MDG1 has reported negative net income.

MDG1 had a negative operating cash flow in the past year.

MDG1 had negative earnings in each of the past 5 years.

In the past 5 years MDG1 reported 4 times negative operating cash flow.

1.2 Ratios

With a Return On Assets value of -56.15%, MDG1 is not doing good in the industry: 62.50% of the companies in the same industry are doing better.

MDG1 has a Return On Equity of -82.28%. This is comparable to the rest of the industry: MDG1 outperforms 45.83% of its industry peers.

		Industry Rank	Sector Rank
ROA	-56.15%
ROE	-82.28%
ROIC	N/A

ROA(3y)-27.97%

ROA(5y)-28.16%

ROE(3y)-40.52%

ROE(5y)-40.06%

ROIC(3y)N/A

ROIC(5y)N/A

1.3 Margins

MDG1 has a Gross Margin of 72.77%. This is in the better half of the industry: MDG1 outperforms 69.44% of its industry peers.

MDG1's Gross Margin has declined in the last couple of years.

MDG1 does not have Profit Margin and Operating Margin available, so we won't be analyzing them here.

		Industry Rank	Sector Rank
OM	N/A
PM (TTM)	N/A
GM	72.77%

OM growth 3YN/A

OM growth 5YN/A

PM growth 3YN/A

PM growth 5YN/A

GM growth 3Y-5.13%

GM growth 5Y-3.96%

More info and screens

ROA

ROE

ROIC

Operating and Profit Margin

Show most profitable peers

2. Health

2.1 Basic Checks

MDG1 does not have a ROIC to compare to the WACC, probably because it is not profitable.

Compared to 1 year ago, MDG1 has about the same amount of shares outstanding.

MDG1 has a worse debt/assets ratio than last year.

2.2 Solvency

Based on the Altman-Z score of -25.08, we must say that MDG1 is in the distress zone and has some risk of bankruptcy.

MDG1 has a Altman-Z score of -25.08. This is amonst the worse of the industry: MDG1 underperforms 83.33% of its industry peers.

MDG1 has a Debt/Equity ratio of 0.08. This is a healthy value indicating a solid balance between debt and equity.

MDG1's Debt to Equity ratio of 0.08 is fine compared to the rest of the industry. MDG1 outperforms 70.83% of its industry peers.

		Industry Rank	Sector Rank
Debt/Equity	0.08
Debt/FCF	N/A
Altman-Z	-25.08

ROIC/WACCN/A

WACC7.78%

2.3 Liquidity

MDG1 has a Current Ratio of 2.39. This indicates that MDG1 is financially healthy and has no problem in meeting its short term obligations.

MDG1 has a Current ratio of 2.39. This is comparable to the rest of the industry: MDG1 outperforms 54.17% of its industry peers.

A Quick Ratio of 2.39 indicates that MDG1 has no problem at all paying its short term obligations.

MDG1 has a better Quick ratio (2.39) than 61.11% of its industry peers.

		Industry Rank	Sector Rank
Current Ratio	2.39
Quick Ratio	2.39

More info and screens

WACC

Debt/Equity

How to determine the health of a company

Altman-Z score

Show peers with great health

3. Growth

3.1 Past

MDG1 shows a strong negative growth in Earnings Per Share. In the last year the EPS decreased by -94.19%.

MDG1 shows a very negative growth in Revenue. In the last year, the Revenue has decreased by -80.69%.

The Revenue has been decreasing by -4.89% on average over the past years.

EPS 1Y (TTM)-94.19%

EPS 3YN/A

EPS 5YN/A

EPS Q2Q%-91.4%

Revenue 1Y (TTM)-80.69%

Revenue growth 3Y-11.65%

Revenue growth 5Y-4.89%

Sales Q2Q%-6%

3.2 Future

MDG1 is expected to show quite a strong growth in Earnings Per Share. In the coming years, the EPS will grow by 12.04% yearly.

MDG1 is expected to show a strong growth in Revenue. In the coming years, the Revenue will grow by 20.49% yearly.

EPS Next Y38.46%

EPS Next 2Y20.82%

EPS Next 3Y18.2%

EPS Next 5Y12.04%

Revenue Next Year100%

Revenue Next 2Y90.69%

Revenue Next 3Y13.3%

Revenue Next 5Y20.49%

3.3 Evolution

The Revenue growth rate is accelerating: in the next years the growth will be better than in the last years.

More info and screens

Find the best growth stocks

Show best growing peers

4. Valuation

4.1 Price/Earnings Ratio

MDG1 reported negative earnings for the last year, which makes the Price/Earnings Ratio negative.

Besides the negative Price/Earnings Ratio, also the Forward Price/Earnings Ratio is negative for MDG1. No positive earnings are expected for the next year.

		Industry Rank	Sector Rank
PE	N/A
Fwd PE	N/A

4.2 Price Multiples

		Industry Rank	Sector Rank
P/FCF	N/A
EV/EBITDA	N/A

4.3 Compensation for Growth

A more expensive valuation may be justified as MDG1's earnings are expected to grow with 18.20% in the coming years.

PEG (NY)N/A

PEG (5Y)N/A

EPS Next 2Y20.82%

EPS Next 3Y18.2%

More info and screens

Show best valued peers

5. Dividend

5.1 Amount

No dividends for MDG1!.

		Industry Rank	Sector Rank
Dividend Yield	N/A

More info and screens

Find the best dividend stocks

Show peers with best dividend

MEDIGENE AG

FRA:MDG1 (4/29/2025, 7:00:00 PM)

0.1335

-0.05 (-27.64%)

Chartmill FA Rating

GICS SectorHealth Care

GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences

GICS IndustryBiotechnology

Earnings (Last)04-24 2025-04-24

Earnings (Next)08-12 2025-08-12

Inst Owners2.38%

Inst Owner ChangeN/A

Ins Owners3.36%

Ins Owner ChangeN/A

Market Cap1.99M

Revenue(TTM)6.03M

Net Income(TTM)-16.18M

Analysts82.5

Price Target3.88 (2806.37%)

Short Float %N/A

Short RatioN/A

Dividend

		Industry Rank	Sector Rank
Dividend Yield	N/A

Yearly DividendN/A

Dividend Growth(5Y)N/A

DPN/A

Div Incr Years0

Div Non Decr Years0

Ex-DateN/A

Surprises & Revisions

EPS beat(2)N/A

Avg EPS beat(2)N/A

Min EPS beat(2)N/A

Max EPS beat(2)N/A

EPS beat(4)N/A

Avg EPS beat(4)N/A

Min EPS beat(4)N/A

Max EPS beat(4)N/A

EPS beat(8)N/A

Avg EPS beat(8)N/A

EPS beat(12)N/A

Avg EPS beat(12)N/A

EPS beat(16)N/A

Avg EPS beat(16)N/A

Revenue beat(2)N/A

Avg Revenue beat(2)N/A

Min Revenue beat(2)N/A

Max Revenue beat(2)N/A

Revenue beat(4)N/A

Avg Revenue beat(4)N/A

Min Revenue beat(4)N/A

Max Revenue beat(4)N/A

Revenue beat(8)N/A

Avg Revenue beat(8)N/A

Revenue beat(12)N/A

Avg Revenue beat(12)N/A

Revenue beat(16)N/A

Avg Revenue beat(16)N/A

PT rev (1m)31.03%

PT rev (3m)31.03%

EPS NQ rev (1m)N/A

EPS NQ rev (3m)N/A

EPS NY rev (1m)0%

EPS NY rev (3m)0%

Revenue NQ rev (1m)N/A

Revenue NQ rev (3m)N/A

Revenue NY rev (1m)0%

Revenue NY rev (3m)0%

Valuation

		Industry Rank	Sector Rank
PE	N/A
Fwd PE	N/A
P/S	0.33
P/FCF	N/A
P/OCF	N/A
P/B	0.1
P/tB	0.2
EV/EBITDA	N/A

EPS(TTM)-1.25

EYN/A

EPS(NY)-0.81

Fwd EYN/A

FCF(TTM)-1.49

FCFYN/A

OCF(TTM)-1.47

OCFYN/A

SpS0.41

BVpS1.32

TBVpS0.66

PEG (NY)N/A

PEG (5Y)N/A

Graham NumberN/A

Profitability

		Industry Rank	Sector Rank
ROA	-56.15%
ROE	-82.28%
ROCE	N/A
ROIC	N/A
ROICexc	N/A
ROICexgc	N/A
OM	N/A
PM (TTM)	N/A
GM	72.77%
FCFM	N/A

ROA(3y)-27.97%

ROA(5y)-28.16%

ROE(3y)-40.52%

ROE(5y)-40.06%

ROIC(3y)N/A

ROIC(5y)N/A

ROICexc(3y)N/A

ROICexc(5y)N/A

ROICexgc(3y)N/A

ROICexgc(5y)N/A

ROCE(3y)N/A

ROCE(5y)N/A

ROICexgc growth 3YN/A

ROICexgc growth 5YN/A

ROICexc growth 3YN/A

ROICexc growth 5YN/A

OM growth 3YN/A

OM growth 5YN/A

PM growth 3YN/A

PM growth 5YN/A

GM growth 3Y-5.13%

GM growth 5Y-3.96%

F-Score1

Asset Turnover0.21

Health

		Industry Rank	Sector Rank
Debt/Equity	0.08
Debt/FCF	N/A
Debt/EBITDA	N/A
Cap/Depr	21.34%
Cap/Sales	5.29%
Interest Coverage	N/A
Cash Conversion	N/A
Profit Quality	N/A
Current Ratio	2.39
Quick Ratio	2.39
Altman-Z	-25.08

F-Score1

WACC7.78%

ROIC/WACCN/A

Cap/Depr(3y)17.88%

Cap/Depr(5y)24.26%

Cap/Sales(3y)5.12%

Cap/Sales(5y)6.87%

Profit Quality(3y)N/A

Profit Quality(5y)N/A

High Growth Momentum

Growth

EPS 1Y (TTM)-94.19%

EPS 3YN/A

EPS 5YN/A

EPS Q2Q%-91.4%

EPS Next Y38.46%

EPS Next 2Y20.82%

EPS Next 3Y18.2%

EPS Next 5Y12.04%

Revenue 1Y (TTM)-80.69%

Revenue growth 3Y-11.65%

Revenue growth 5Y-4.89%

Sales Q2Q%-6%

Revenue Next Year100%

Revenue Next 2Y90.69%

Revenue Next 3Y13.3%

Revenue Next 5Y20.49%

EBIT growth 1Y-85.05%

EBIT growth 3YN/A

EBIT growth 5YN/A

EBIT Next Year34.4%

EBIT Next 3Y12.36%

EBIT Next 5Y9.43%

FCF growth 1Y-262.89%

FCF growth 3YN/A

FCF growth 5YN/A

OCF growth 1Y-257.03%

OCF growth 3YN/A

OCF growth 5YN/A

MEDIGENE AG / MDG1.DE FAQ

What is the ChartMill fundamental rating of MEDIGENE AG (MDG1.DE) stock?

ChartMill assigns a fundamental rating of 2 / 10 to MDG1.DE.

What is the valuation status for MDG1 stock?

ChartMill assigns a valuation rating of 0 / 10 to MEDIGENE AG (MDG1.DE). This can be considered as Overvalued.

How profitable is MEDIGENE AG (MDG1.DE) stock?

MEDIGENE AG (MDG1.DE) has a profitability rating of 1 / 10.

Can you provide the financial health for MDG1 stock?

The financial health rating of MEDIGENE AG (MDG1.DE) is 4 / 10.

Can you provide the expected EPS growth for MDG1 stock?

The Earnings per Share (EPS) of MEDIGENE AG (MDG1.DE) is expected to grow by 38.46% in the next year.

MEDIGENE AG (MDG1.DE) Stock Fundamental Analysis

1. Profitability

1.1 Basic Checks

1.2 Ratios

1.3 Margins

More info and screens

2. Health

2.1 Basic Checks

2.2 Solvency

2.3 Liquidity

More info and screens

3. Growth

3.1 Past

3.2 Future

3.3 Evolution

More info and screens

4. Valuation

4.1 Price/Earnings Ratio

4.2 Price Multiples

4.3 Compensation for Growth

More info and screens

5. Dividend

5.1 Amount

More info and screens

MEDIGENE AG / MDG1.DE FAQ

What is the ChartMill fundamental rating of MEDIGENE AG (MDG1.DE) stock?

What is the valuation status for MDG1 stock?

How profitable is MEDIGENE AG (MDG1.DE) stock?

Can you provide the financial health for MDG1 stock?

Can you provide the expected EPS growth for MDG1 stock?